China ranks 2nd globally in new drug development, NHC official says
China now ranks second globally in new drug development, accounting for 20 percent of the world's new pharmaceuticals in the pipeline, a health official said on Thursday.
Guo Yanhong, an official of the National Health Commission, said at a press conference that several domestically developed innovative drugs for cancer treatment have received market approval both in China and abroad.
Locally produced human papillomavirus vaccines have also been widely adopted, significantly improving vaccine accessibility.
Meanwhile, a range of domestic medical devices — from advanced CT scanners and surgical robots to artificial hearts and proton and heavy ion radiotherapy systems — have been successfully developed and put into clinical use.
"The overall capacity of health science and technology has continued to strengthen, resulting in a series of groundbreaking advances and landmark achievements," she added.
- Beijing-Pyongyang passenger rail service to resume Thursday
- Shanghai and Jiangsu integration boosts sports-tourism development
- China Eastern Airlines restores direct flights between Shanghai and Stockholm
- RedNote targets AI-run accounts with new governance rules
- China's draft law on ethnic unity aims to serve as global model, political adviser
- Spring blossoms complement the Honghe Hani Rice Terraces in Yunnan































